Home » Stocks » MDXG

MiMedx Group, Inc. (MDXG)

Stock Price: $5.60 USD -0.15 (-2.61%)
Updated Oct 30, 2020 11:34 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 621.80M
Revenue (ttm) 280.65M
Net Income (ttm) -8.38M
Shares Out 111.04M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $5.60
Previous Close $5.75
Change ($) -0.15
Change (%) -2.61%
Day's Open 5.75
Day's Range 5.60 - 5.94
Day's Volume 17,737
52-Week Range 2.95 - 7.67

More Stats

Market Cap 621.80M
Enterprise Value 638.83M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 111.04M
Float 93.53M
EPS (basic) -0.07
EPS (diluted) -0.08
FCF / Share -0.41
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 61.28M
Short Ratio 21.80
Short % of Float 65.52%
Beta 1.24
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.22
PB Ratio 28.17
Revenue 280.65M
Operating Income -10.27M
Net Income -8.38M
Free Cash Flow -43.93M
Net Cash -17.03M
Net Cash / Share -0.15
Gross Margin 91.28%
Operating Margin -3.66%
Profit Margin -3.00%
FCF Margin -15.65%
ROA 7.58%
ROE -35.27%
ROIC -14.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$9.00*
Low
9.00
Current: $5.60
High
9.00
Target: 9.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue29935932124518711859.1827.057.760.79
Revenue Growth-16.67%11.82%31.07%30.82%58.43%99.77%118.76%248.6%883.74%-
Gross Profit25632328621316710649.8521.874.40-0.93
Operating Income-21.16-3.9246.2218.1124.367.10-2.64-3.79-9.76-10.53
Net Income-25.58-29.9864.7311.9729.456.22-4.11-7.66-10.19-11.42
Shares Outstanding10710610610610610696.2981.6572.4559.14
Earnings Per Share-0.24-0.280.560.110.260.05-0.04-0.09-0.14-0.19
EPS Growth--409.09%-57.69%420%-----
Operating Cash Flow-39.4135.8062.9425.8318.8116.80-0.28-3.33-6.66-8.16
Capital Expenditures-1.75-9.39-5.13-6.27-5.83-2.56-2.34-0.64-0.49-0.15
Free Cash Flow-41.1626.4157.8119.5612.9814.24-2.62-3.97-7.15-8.31
Cash & Equivalents69.0745.12-34.3931.4952.3344.086.754.111.34
Total Debt65.66------4.015.170.40
Net Cash / Debt3.4145.12-34.3931.4952.3344.082.74-1.060.94
Assets167123-19313610984.6935.1827.107.35
Liabilities13373.19-60.2627.9319.9311.1315.1815.201.25
Book Value34.4049.66-13310889.3373.5720.0111.906.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MiMedx Group, Inc.
Country United States
Employees 696
CEO Timothy R. Wright

Stock Information

Ticker Symbol MDXG
Stock Exchange US OTC
Sector Healthcare
Industry Medical Devices
Unique Identifier OTCMKTS: MDXG

Description

MiMedx Group, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, arterial ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill, a connective tissue matrix derived from placental disc, umbilical cord, and amnion/chorion tissues. Its products have applications in the areas of wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. The company sells its products through direct sales force, independent sales agents, and third party representatives, as well as independent distributors. MiMedx Group, Inc. is headquartered in Marietta, Georgia.